Literature DB >> 26668336

Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials.

Joseph G Toerner1, Edward Cox1.   

Abstract

Keywords:  antibacterial drug development; clinical endpoints; non-inferiority trial design

Mesh：

Substances：

Year:  2015        PMID： 26668336      PMCID： PMC4741355          DOI： 10.1093/cid/civ1007

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Early endpoints for acute bacterial skin and skin structure infections.

Authors:  George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 2.  FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.

Authors:  Kamal M F Itani; Andrew F Shorr
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

3.  Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Authors:  G Ralph Corey; Samantha Good; Hai Jiang; Greg Moeck; Matthew Wikler; Sinikka Green; Paul Manos; Richard Keech; Rajesh Singh; Barry Heller; Natalia Bubnova; William O'Riordan
Journal:  Clin Infect Dis       Date:  2014-10-06       Impact factor: 9.079

4.  Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Authors:  Andrew F Shorr; Thomas P Lodise; G Ralph Corey; Carisa De Anda; Edward Fang; Anita F Das; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

5.  Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Authors:  Helen W Boucher; Mark Wilcox; George H Talbot; Sailaja Puttagunta; Anita F Das; Michael W Dunne
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.